BioDelivery Sciences International, Inc.
| Nasdaq: BDSI
BioDelivery Sciences International, Inc. is a pharmaceutical company with a focus in the areas of pain management and addiction medicine. Its products include: BioErodible MucoAdhesive technology and BEMA Buprenorphine is being developed for the treatment of moderate to severe chronic pain and is in development in a high dose formulation with naloxone for the treatment of opioid dependence. The company's other products include BEMA Buprenorphine/Naloxone used for the treatment of opioid dependency and BEMA Granisetron used for the prevention of nausea and vomiting associated with cancer therapies. The company was founded on January 6, 1997 and is headquartered in Raleigh, NC.